Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1429-1436

  Hutson, Paul R ^a,b   Tutsch, Rendra D ^a   Rago, Randall ^a   Arzoomanian, Rhoda ^a   Alberti, Dona ^a   Pomplun, Marcia ^a   Church, Dawn ^a   Marnocha, Rebecca ^a   Cheng, An Li ^a   Kehrli, Nancy ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; SURAMIN;

ADULT; AGED; ARTICLE; BRAIN BIOPSY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG EFFECT; DRUG MONITORING; ENZYME ACTIVITY; FEMALE; GENE TARGETING; HUMAN; HUMAN TISSUE; INDIVIDUALIZATION; KIDNEY CLEARANCE; MALE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADULT; AFFECT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CA-125 ANTIGEN; FEMALE; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; SURAMIN; TISSUE DISTRIBUTION;

EID: 0031749760     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Stein, C. A. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res., 53: 2239-2248, 1993.
2. Myers, C., Cooper, M., Stein, C., LaRocca, R., Walther, M. M., Weiss, G., Choyke, P., Dawson, N., Steinberg, S., Uhrich, M. M., Cassidy, J., Kohler, D. R., Trepel, J., and Linehan, W. M. Suramin: a novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer. J. Clin. Oncol., 10: 881-889, 1992.
3. LaRocca, R., Meer, J., Gillatt, R. W., Stein, C. A., Cassidy, J., Myers, C. E., and Dalakas, M. C. Suramin-induced polyneuropathy. Neurology, 40: 954-960, 1990.
4. Bitton, R. J., Figg, W. D., Venzon, D. J., Dalakas, M. C., Bowden, C., Headlee, D., Reed, E., Myers, C. E., and Cooper, M. R. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J. Clin. Oncol., 13: 2223-2229, 1995.
5. Scher, H., Jodrell, D., Iversen, J., Curley, T., Tong, W., Egorin, M. J., and Forrest, A. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res., 52: 64-70, 1992.
6. Cooper, M., Lieberman, R., LaRocca, R., Gernt, P. R., Weinberger, M. S., Headlee, D. J., Kohler, D. R., Goldspiel, B. R., Peck, C. C., and Myers, C. E. Adaptive control with feedback strategies for suramin dosing. Clin. Pharmacol. Ther., 52: 11-23, 1992.
7. Jodrell, D. I., Reyno, L. M., Sridhara, R., Eisenberger, M. A., Tkaczuk, K. H., Zuhowski, E. G., Sinibaldi, V. J., Novak, M. J., and Egorin, M. J. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J. Clin. Oncol., 12: 166-175, 1994.
8. Collins, J. M., Klecker, R. J., Yarchoan, R., Lane, H. C., Fauci, A. S., Redfield, R. R., Broder, S., and Myers, C. E. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J. Clin. Pharmacol., 26: 22-26, 1986.
9. Hutson, P., Arzoomanian, R., Tombes, M. B., Alberti, D., Tutsch, K., Mutch, R., Rago, R., Cheng, A. L., Spriggs, D., and Wilding, G. Test dose guided rapid IV suramin infusions with weekly IV maintenance doses. Proc. Am. Soc. Clin. Oncol., 10: 99, 1991.
10. Rago, R., Tutsch, K., Pomplun, M., Hutson, P., and Wilding, G. Human plasma and tissue levels of suramin. Proc. Am. Assoc. Cancer Res., 33: 429, 1992.
11. Hutson, P. R., Rago, R., Arzoomanian, R., Alberti, D., Tombes, M. B., Spriggs, D., and Wilding, G. Use of probe drugs to evaluate the effect of suramin on P450 activity. Proc. Am. Assoc. Cancer Res., 33; 532, 1992.
12. Hutson, P. R., Tutsch, K. D., Rago, R., Arzoomanian, R., Alberti, D., Feierabend, C., Pomplun, M., Spriggs, D., and Wilding, G. Suramin clearance prediction by limited sampling methods or by creatinine clearance. Proc. Am. Assoc. Cancer Res., 34: 397, 1993.
13. Hutson, P. R., Kehrli, N., Alberti, D., Arzoomanian, R., Feierabend, C., Tutsch, K., and Wilding, G. Suramin does not inhibit hepatic P450IID6 metabolism. Proc. Am. Assoc. Cancer Res., 35: 242, 1994.
14. Hutson, P. R., Tutsch, K. D., and Wilding, G. Pharmacokinetic analysis and adaptive control of suramin. In: D. Z. D'Argenio (ed.), Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, pp. 177-187. New York: Plenum Press, 1995.
15. Rago, R. P., Miles, J. M., Sufit, R. L., Spriggs, D. R., and Wilding, G. Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Cancer (Phila.), 73: 1954-1959, 1994.
16. Hutson, P. R., Tutsch, K., Spriggs, D., Christian, M., Rago, R., Mutch, R., and Wilding, G. Evidence of an absorption phase after short intravenous suramin infusions. Cancer Chemother. Pharmacol., 31: 495-499, 1993.
17. van Rijn, J. L., Trillou, M., Mardiguian, J., Tobelem, G., and Caen, J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb. Res., 45: 211-222, 1987.
18. Barzu, T., Van Rijn, J. L., Petitou, M., Molho, P., Tobelem, G., and Caen, J. P. Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem. J., 238: 847-854, 1986.
19. Klecker, R. W., and Collins, J. M. Quantification of suramin by reverse-phase ion-pairing high performance liquid chromatography. J. Liq. Chromatogr., 8: 1685-1696, 1985.
20. Supko, J. G., and Malspeis, L. A rapid isocratic HPLC assay of suramin (NSC 34936) in human plasma. J. Liq. Chromatogr., 13: 727-741, 1990.
21. D'Argenio, D. Z., and Schumitzky, A. ADAPT II User's Guide. Los Angeles, CA: Biomedical Simulations Resource, University of Southern California, 1992.
22. Akaike, H. An information criterion (AIC). Math Sci., 14: 5-9, 1976.
23. Schmid, B., Bircher, J., Presig, R., and Kupfer, A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther., 38: 618-624, 1985.
24. Tang, B. K., Kadar, D., and Kalow, W. An alternative test for acetylator phenotyping with caffeine. Clin. Pharmacol. Ther., 42: 509-513, 1987.
25. Uetrecht, J., Zahid, N., Shear, N. H., and Biggar, W. D. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J. Pharmacol. Exp. Ther., 245: 274-279, 1988.
26. Wedlund, P. J., Asianian, W. S., McAllister, C. B., Wilkinson, G. R., and Branch, R. A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther., 36: 773-780, 1984.
27. Chen, Z. R., Somogyi, A. A., and Bochner, F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther. Drug Monitor., 12: 97-104, 1990.
28. Denaro, C. P., Wilson, M., Jacob, P., and Benowitz, N. L. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Clin. Pharmacol. Ther., 59: 284-296, 1996.
29. Gorski, J. C., Jones, D. R., Wrighton, S. A., and Hall, S. D. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol., 48: 173-182, 1994.
30. Jones, D. R., Gorski, J. C., Haehner, B. D., O'Mara, E. M., Jr., and Hall, S. D. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin. Pharmacol. Ther., 60: 374-384, 1996.
31. Reyno, L. M., Egorin, M. J., Eisenberger, M. A., Sinibaldi, V. J., Zuhowski, E. G., and Sridhara, R. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J. Clin. Oncol., 13: 2187-2195, 1995.
32. Kobayashi, K., Vokes, E. E., Vogelzang, N. J., Janisch, L., Soliven, B., and Ratain, M. J. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J. Clin. Oncol., 13: 2196-2207, 1995.
33. Eisenberger, M. A., Sinibaldi, V. J., Reyno, L. M., Sridhara, R., Jodrell, D. I., Zuhowski, E. G., Tkaczuk, K. H., Lowitt, M. H., Hemady, R. K., Jacobs, S. C., VanEcho, D., and Egorin, M. J. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J. Clin. Oncol., 13: 2174-2186, 1995.
34. van Rijswijk, R. E. N., van Loenen, A. C., Wagstaff, J., Meijer, E., Lopez, R., van Groeningen, C. J., Heimans, J. J., and Pinedo, H. M. Suramin: rapid loading and weekly maintenance regimens for cancer patients. J. Clin. Oncol., 10: 1788-1794, 1992.